Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option
Immunotherapy is one of the promising strategies in the treatment of oncology. Immune checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical treatment of patients with pMMR/MSS/MSI-L mCRC alone. Therefore, there is an urgent need to find combination therapies...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.961796/full |
| _version_ | 1828759717233557504 |
|---|---|
| author | Yi Ren Jia-Meng Miao Yuan-Yuan Wang Yuan-Yuan Wang Zheng Fan Xian-Bin Kong Long Yang Long Yang Gong Cheng Gong Cheng |
| author_facet | Yi Ren Jia-Meng Miao Yuan-Yuan Wang Yuan-Yuan Wang Zheng Fan Xian-Bin Kong Long Yang Long Yang Gong Cheng Gong Cheng |
| author_sort | Yi Ren |
| collection | DOAJ |
| description | Immunotherapy is one of the promising strategies in the treatment of oncology. Immune checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical treatment of patients with pMMR/MSS/MSI-L mCRC alone. Therefore, there is an urgent need to find combination therapies that can improve the response rate of immune checkpoint inhibitors. Oncolytic viruses are a new class of cancer drugs that, in addition to directly lysing tumor cells, can facilitate the action of immune checkpoint inhibitors by modulating the tumor microenvironment and transforming “cold” tumors into “hot” ones. The combination of oncolytic viruses and immune checkpoint inhibitors is currently being used in several primary and clinical studies to treat tumors with exciting results. The combination of genetically modified “armed” OV with ICIs is expected to be one of the treatment options for pMMR/MSS/MSI-L mCRC. In this paper, we will analyze the current status of oncolytic viruses and ICIs available for the treatment of CRC. The feasibility of OV in combination with ICI for CRC will be discussed in terms of the mechanism of action of OV in treating tumors. |
| first_indexed | 2024-12-11T01:01:39Z |
| format | Article |
| id | doaj.art-3bfd34ed6c6646a5a9333f9e2c61ed42 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T01:01:39Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3bfd34ed6c6646a5a9333f9e2c61ed422022-12-22T01:26:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.961796961796Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment optionYi Ren0Jia-Meng Miao1Yuan-Yuan Wang2Yuan-Yuan Wang3Zheng Fan4Xian-Bin Kong5Long Yang6Long Yang7Gong Cheng8Gong Cheng9College of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaCollege of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaResearch Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaDepartment of Critical Medicine, The First Affiliated Hospital of Suzhou University, Suzhou, ChinaCollege of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaResearch Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaTsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, ChinaInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, ChinaImmunotherapy is one of the promising strategies in the treatment of oncology. Immune checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical treatment of patients with pMMR/MSS/MSI-L mCRC alone. Therefore, there is an urgent need to find combination therapies that can improve the response rate of immune checkpoint inhibitors. Oncolytic viruses are a new class of cancer drugs that, in addition to directly lysing tumor cells, can facilitate the action of immune checkpoint inhibitors by modulating the tumor microenvironment and transforming “cold” tumors into “hot” ones. The combination of oncolytic viruses and immune checkpoint inhibitors is currently being used in several primary and clinical studies to treat tumors with exciting results. The combination of genetically modified “armed” OV with ICIs is expected to be one of the treatment options for pMMR/MSS/MSI-L mCRC. In this paper, we will analyze the current status of oncolytic viruses and ICIs available for the treatment of CRC. The feasibility of OV in combination with ICI for CRC will be discussed in terms of the mechanism of action of OV in treating tumors.https://www.frontiersin.org/articles/10.3389/fimmu.2022.961796/fulloncolytic virusesimmune checkpoint inhibitorcolorectal cancertumor microenvironmentimmunotherapy |
| spellingShingle | Yi Ren Jia-Meng Miao Yuan-Yuan Wang Yuan-Yuan Wang Zheng Fan Xian-Bin Kong Long Yang Long Yang Gong Cheng Gong Cheng Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option Frontiers in Immunology oncolytic viruses immune checkpoint inhibitor colorectal cancer tumor microenvironment immunotherapy |
| title | Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option |
| title_full | Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option |
| title_fullStr | Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option |
| title_full_unstemmed | Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option |
| title_short | Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option |
| title_sort | oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option |
| topic | oncolytic viruses immune checkpoint inhibitor colorectal cancer tumor microenvironment immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.961796/full |
| work_keys_str_mv | AT yiren oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT jiamengmiao oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT yuanyuanwang oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT yuanyuanwang oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT zhengfan oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT xianbinkong oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT longyang oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT longyang oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT gongcheng oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption AT gongcheng oncolyticvirusescombinedwithimmunecheckpointtherapyforcolorectalcancerisapromisingtreatmentoption |